CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vivani Medical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vivani Medical Inc
1350 S. LOOP ROAD
Phone: (415) 506-8462p:415 506-8462 ALAMEDA, CA  94502  United States Ticker: VANIVANI
Business Summary
Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Gregg G.Williams 64 1/1/2021 6/1/2009
Chief Executive Officer, Director AdamMendelsohn 41 8/30/2022 8/30/2022
Chief Financial Officer Brigid A.Makes 67 8/30/2022 8/30/2022
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Nano Precision Medical, Inc. 5858 Horton St Emeryville CA United States

Business Names
Business Name
Cortigent, Inc.
EYES
Second Sight Medical Products
Second Sight Medical Products
VANI
Vivani Medical Australia Pty Ltd

General Information
Number of Employees: 44 (As of 12/31/2023)
Outstanding Shares: 59,234,689 (As of 11/12/2024)
Shareholders: 110
Stock Exchange: NASD
Federal Tax Id: 020692322


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024